America stands at a pivotal moment in biotechnology and scientific innovation. The National Security Commission on Emerging Biotechnology (NSCEB),...
Read PostAdvocacy
Championing Bio-Industry Progress
Stay informed on advocacy efforts driving growth and innovation in the bio-industry. This category features updates, initiatives, and insights focused on promoting policies and actions that support our thriving community.
On December 1, 2025, Washington and London announced an “agreement in principle” that does two big things at once: it shields...
Read PostThe Advanced Research Projects Agency for Health (ARPA-H) – Health & Human Service (HHS)’s “high-risk, high-reward”...
Read PostAfter the FDA’s Rare Pediatric Disease (RPD) Priority Review Voucher (PRV) authority lapsed at the end of 2024, patient groups and drug...
Read PostA major bipartisan push to overhaul pharmacy benefit managers (PBMs) is back on the Senate agenda. On Dec. 4, Senate Finance Committee...
Read PostIn a recent Detroit Free Press op-ed, MichBio CEO, Stephen Rapundalo, responded to an article by the CEO of Blue Cross Blue Shield of Michigan...
Read PostOn October 30, 2025, the Michigan House Regulatory Reform Committee voted 13-0-2 to discharge House Bill 4254. The bill, introduced by Rep....
Read PostOn October 9, 2025, the U.S. Senate took a major step toward embedding a retooled BIOSECURE Act into national policy by approving it as an...
Read PostThe U.S. Department of Commerce’s decision to launch a Section 232 investigation into imports of medical devices and related equipment has...
Read PostThe Trump Administration has chosen to uphold NIH’s new “access planning” licensing guidelines, a regulatory shift...
Read PostThe September 30, 2025, announcement that Pfizer will cut prices on selected drugs (particularly for Medicaid and uninsured populations), tied...
Read PostOn August 7, 2025, the Administration issued Executive Order 14332 – Improving Oversight of Federal Grantmaking - marking a fundamental...
Read Post